0001140361-22-028193.txt : 20220804 0001140361-22-028193.hdr.sgml : 20220804 20220804160609 ACCESSION NUMBER: 0001140361-22-028193 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220804 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220804 DATE AS OF CHANGE: 20220804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PDS Biotechnology Corp CENTRAL INDEX KEY: 0001472091 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 264231384 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37568 FILM NUMBER: 221136478 BUSINESS ADDRESS: STREET 1: 25B VREELAND ROAD STREET 2: SUITE 300 CITY: FLORHAM PARK STATE: NJ ZIP: 07932 BUSINESS PHONE: 800-208-3343 MAIL ADDRESS: STREET 1: 25B VREELAND ROAD STREET 2: SUITE 300 CITY: FLORHAM PARK STATE: NJ ZIP: 07932 FORMER COMPANY: FORMER CONFORMED NAME: Edge Therapeutics, Inc. DATE OF NAME CHANGE: 20090911 8-K 1 brhc10040417_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

 
FORM 8-K

 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 4, 2022


PDS BIOTECHNOLOGY CORPORATION
(Exact Name of Registrant as Specified in Charter)


Delaware
001-37568
26-4231384
     
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)

25B Vreeland Road, Suite 300, Florham Park, NJ 07932
 (Address of Principal Executive Offices, and Zip Code)
(800) 208-3343
Registrant’s Telephone Number, Including Area Code


(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    
Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.00033 per share
PDSB
The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐

Item 8.01
Other Events.

On August 4, 2022, PDS Biotechnology Corporation issued a press release announcing its independent Data Monitoring Committee (DMC) met for its scheduled review of PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for the potential treatment of recurrent or metastatic HPV16-positive head and neck cancer. Based on their review of patients with available safety data, the DMC recommended continuing the trial without modifications because PDS0101 in combination with KEYTRUDA® continues to appear safe and well tolerated.

A copy of the press release is filed herewith as Exhibit 99.1 and incorporated by reference herein.

Item 9.01
Financial Statements and Exhibits.

(d)
Exhibits.

Exhibit
Number
  
Description
     
 
Press Release Dated August 4, 2022.
104
  
Cover Page Interactive Data File (embedded within the Inline XBRL Document)
 
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
PDS BIOTECHNOLOGY CORPORATION
   
Date: August 4, 2022
By: /s/ Frank Bedu-Addo, Ph.D.
 
Name: Frank Bedu-Addo, Ph.D.
 
Title: President and Chief Executive Officer


EX-99.1 2 brhc10040417_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1
 
PDS Biotech Independent Data Monitoring Committee Recommends VERSATILE-002 Trial Continuation without Modifications

Safety evaluation of 43 patients with no grade 3 or higher treatment-related adverse events
 
FLORHAM PARK, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T cell activating technologies, today announced that its independent Data Monitoring Committee (DMC) met for its scheduled review of PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for the potential treatment of recurrent or metastatic HPV16-positive head and neck cancer.
 
Data from the 43 patients included both Stage 1 and Stage 2 checkpoint inhibitor (CPI) naïve subjects and Stage 1 CPI refractory subjects in the safety analysis. Assessment of clinical efficacy was not a focus of the DMC meeting review. Based on their review of patients with available safety data, PDS0101 in combination with KEYTRUDA® continues to appear safe and well tolerated. Specifically, there were no drug discontinuations related to toxicity as of the DMC review. In addition, there were no Grade 3 or greater treatment-related adverse events attributed to the combination. The DMC recommended continuing the trial with no modifications.
 
“The safety profile of PDS0101 in combination with KEYTRUDA® was consistent with previously reported studies of KEYTRUDA® alone.” mentioned Dr. Lauren V. Wood, Chief Medical Officer of PDS Biotech. “The safety data in patients with recurrent or metastatic HPV16-positive head and neck cancer continues to appear to be well tolerated. We look forward to evaluating this further in the VERSATILE-002 trial.”
 
VERSATILE-002 enrollment has progressed to Stage 2 for the checkpoint inhibitor (CPI) naive cohort and is ongoing in Stage 1 for the CPI refractory cohort. The DMC is comprised of an independent group of clinical and scientific leaders in the field of immuno-oncology and is responsible for reviewing and evaluating patient safety and efficacy data in the Phase 2 VERSATILE-002 trial.
 
KEYTRUDA® is a registered trademark of Merck Sharp and Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
 
About VERSATILE-002
 
VERSATILE-002 is a single-arm Phase 2 trial evaluating the safety and efficacy of PDS0101, an HPV16-targeted investigational T cell-activating immunotherapy that leverages PDS Biotech’s proprietary Versamune® technology, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). The combination is being evaluated in CPI-naïve and CPI-refractory patients with recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC) and was granted Fast Track designation by the Food and Drug Administration in June 2022.
 
In June 2022, preliminary efficacy and safety data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting for CPI-naïve patients (PR link). Preliminary data from the first 19 patients demonstrated that 77% of the patients with available imaging (17 of 19) had either disease stabilization or tumor shrinkage. Additionally, the overall survival rate of these patients at 9-months was 87%.
 
About PDS Biotechnology
 
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on the Company’s proprietary Versamune® and Infectimune™ T cell activating technology platforms. We believe our Versamune® based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The Company continues to advance its pipeline of candidates to address a wide range of cancers including HPV16-associated cancers (anal, cervical, head and neck, penile, vaginal, vulvar) and breast, colon, lung, prostate and ovarian cancers.
 
Our Infectimune™ based vaccines have demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses including long-lasting memory T cell responses. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
 
Forward Looking Statements
 
This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101, PDS0203 and other Versamune® and Infectimune™based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101, PDS0203 and other Versamune® and Infectimune™based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
 
Versamune® is a registered trademark and Infectimune™ is a trademark of PDS Biotechnology.
 
Investor Contacts:
Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
drandolph@pdsbiotech.com

Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: pdsb@cg.capital


 EX-101.SCH 3 pdsb-20220804.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 pdsb-20220804_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 pdsb-20220804_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document and Entity Information
Aug. 04, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 04, 2022
Entity File Number 001-37568
Entity Registrant Name PDS BIOTECHNOLOGY CORPORATION
Entity Central Index Key 0001472091
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 26-4231384
Entity Address, Address Line One 25B Vreeland Road
Entity Address, Address Line Two Suite 300
Entity Address, City or Town Florham Park
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07932
City Area Code 800
Local Phone Number 208-3343
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.00033 per share
Trading Symbol PDSB
Security Exchange Name NASDAQ
XML 7 brhc10040417_8k_htm.xml IDEA: XBRL DOCUMENT 0001472091 2022-08-04 2022-08-04 false 0001472091 NASDAQ 8-K 2022-08-04 PDS BIOTECHNOLOGY CORPORATION DE 001-37568 26-4231384 25B Vreeland Road Suite 300 Florham Park NJ 07932 800 208-3343 false false false false Common Stock, par value $0.00033 per share PDSB false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 23 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://pdsbiotech.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports brhc10040417_8k.htm brhc10040417_ex99-1.htm pdsb-20220804.xsd pdsb-20220804_lab.xml pdsb-20220804_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc10040417_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "brhc10040417_8k.htm" ] }, "labelLink": { "local": [ "pdsb-20220804_lab.xml" ] }, "presentationLink": { "local": [ "pdsb-20220804_pre.xml" ] }, "schema": { "local": [ "pdsb-20220804.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "pdsb", "nsuri": "http://pdsbiotech.com/20220804", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc10040417_8k.htm", "contextRef": "c20220804to20220804", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://pdsbiotech.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc10040417_8k.htm", "contextRef": "c20220804to20220804", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "trueItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001140361-22-028193-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-22-028193-xbrl.zip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